Teva’s primary concern is the health and safety of patients and those affected by the war in Ukraine, and we have been supporting all our impacted employees and their families. As a leading pharmaceutical company and one of the largest manufacturers of generic medicines, we have a responsibility to provide treatments to patients who need them, and we remain committed to doing so in a safe and compliant manner.
Last week, we announced a donation of more than $11 million (wholesale acquisition cost) worth of essential medicines for Ukrainian refugees impacted by the war. This includes approximately 27 million doses of medicines, mostly provided in collaboration with Teva's long-term trusted partner, Direct Relief.
We are monitoring the evolving situation and will adjust our operations as needed to continue getting essential medicines to patients.